Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 10:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Group 2 Pulmonary Hypertension Clear all
Withdrawn Not applicable Interventional
View directory record Official record
Conditions
Heart Failure, Pulmonary Hypertension
Interventions
Rivet Shunt
Device
Lead sponsor
NXT Biomedical
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Boston, Massachusetts • Rochester, Minnesota • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 2, 2024 · Synced May 21, 2026, 10:00 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Selexipag, Placebo, Standard of Care (SOC): Endothelin receptor antagonist, SOC: Phosphodiesterase type 5 (PDE-5) inhibitor, SOC: Soluble guanylate cyclase stimulator
Drug
Lead sponsor
Actelion
Industry
Eligibility
2 Years to 17 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 21, 2026, 10:00 PM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
AIR001
Drug
Lead sponsor
Aires Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
17
States / cities
La Jolla, California • Torrance, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced May 21, 2026, 10:00 PM EDT
Withdrawn Phase 1 Interventional
View directory record Official record
Conditions
Pulmonary Artery Hypertension
Interventions
reserpine, stellate ganglion block, lidocaine
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced May 21, 2026, 10:00 PM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Group 2 Pulmonary Hypertension
Interventions
JK07
Drug
Lead sponsor
Salubris Biotherapeutics Inc
Industry
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 21, 2026, 10:00 PM EDT
Enrolling by invitation Not applicable Interventional
View directory record Official record
Conditions
Group 2 Pulmonary Hypertension, Heart Failure
Interventions
Gradient Denervation System
Device
Lead sponsor
Gradient Denervation Technologies
Industry
Eligibility
22 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
8
States / cities
Chicago, Illinois • Boston, Massachusetts • Durham, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 21, 2026, 10:00 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
ubenimex, placebo
Drug · Other
Lead sponsor
Eiger BioPharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
28
States / cities
Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2023 · Synced May 21, 2026, 10:00 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
Interventions
Inhaled Nitric Oxide
Drug
Lead sponsor
Geno LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2016 · Synced May 21, 2026, 10:00 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Pulmonary Hypertension (World Health Organization Group 2), Heart Failure
Interventions
AZD3427, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Beverly Hills, California • La Jolla, California • New Haven, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced May 21, 2026, 10:00 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Pulmonary Artery Hypertension
Interventions
GB002 (seralutinib), Placebo, Generic Dry Powder Inhaler
Drug · Device
Lead sponsor
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
36
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced May 21, 2026, 10:00 PM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
AIR001 (sodium nitrite inhalation solution)
Drug
Lead sponsor
Aires Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
17
States / cities
La Jolla, California • Torrance, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced May 21, 2026, 10:00 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Pulmonary Hypertension Associated With HFpEF
Interventions
TNX-103, Placebo
Drug
Lead sponsor
Tenax Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
18
States / cities
Alexander City, Alabama • Tamarac, Florida • Mount Prospect, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced May 21, 2026, 10:00 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Interventions
Inhaled NO delivered via INOpulse DS-C Device, Placebo delivered via INOpulse DS-C Device
Combination Product
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
40 Years to 80 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
43
States / cities
Jasper, Alabama • Flagstaff, Arizona • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2023 · Synced May 21, 2026, 10:00 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
TNX-103, Placebo
Drug
Lead sponsor
Tenax Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
41
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced May 21, 2026, 10:00 PM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Pulmonary Hypertension Due to Left Heart Disease
Interventions
Treprostinil Diolamine
Drug
Lead sponsor
Mardi Gomberg -Maitland MD, MSc
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Columbus, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced May 21, 2026, 10:00 PM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Pemziviptadil (PB1046)
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
26
States / cities
Mobile, Alabama • Tucson, Arizona • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced May 21, 2026, 10:00 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
ubenimex
Drug
Lead sponsor
Eiger BioPharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
26
States / cities
Beverly Hills, California • La Jolla, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced May 21, 2026, 10:00 PM EDT
Enrolling by invitation Phase 3 Interventional
View directory record Official record
Conditions
Pulmonary Hypertension Associated With HFpEF
Interventions
TNX-103
Drug
Lead sponsor
Tenax Therapeutics, Inc.
Industry
Eligibility
Not listed
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
5
States / cities
Chicago, Illinois • Minneapolis, Minnesota • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced May 21, 2026, 10:00 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
APD811, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced May 21, 2026, 10:00 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Pulmonary Hypertension, Familial Persistent, of the Newborn
Interventions
placebo, iv sildenafil
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
0 Days to 4 Days
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
20
States / cities
Little Rock, Arkansas • Sacramento, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2021 · Synced May 21, 2026, 10:00 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Imatinib, Sildenafil, Bosentan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Tampa, Florida • Weston, Florida • Mineola, New York
Source: ClinicalTrials.gov public record
Updated Jun 20, 2021 · Synced May 21, 2026, 10:00 PM EDT